Severe Cutaneous Adverse Reactions: Acute Generalized Exanthematous Pustulosis, Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome

Medical Clinics of North America

Volumn 94, Issue 4, 2010, Pages 727-742

  Harr, Thomas ^a   French, Lars E ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Acute generalized exanthematous pustulosis; Intravenous immunoglobulins; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

ALLOPURINOL; AMINOPENICILLIN; AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIMALARIAL AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CEPHALOSPORIN DERIVATIVE; CHLORMEZANONE; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; MACROLIDE; NEVIRAPINE; OXICAM DERIVATIVE; PARACETAMOL; PRISTINAMYCIN; QUINOLONE DERIVATIVE; SULFONAMIDE; TERBINAFINE; UNINDEXED DRUG; VALPROIC ACID;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; BULLOUS PEMPHIGOID; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; FNFECTIOUS FOLLICULITIS; FOLLICULITIS; GENETIC SUSCEPTIBILITY; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE; LYMPHOCYTE TRANSFORMATION TEST; NONHUMAN; PATCH TEST; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RASH; REVIEW; SKIN BIOPSY; SKIN MANIFESTATION; SPIDER BITE; STAPHYLOCOCCAL SCALDED SKIN SYNDROME; STEVENS JOHNSON SYNDROME; SUBCORNEAL PUSTULAR DERMATOSIS; TOXIC EPIDERMAL NECROLYSIS; VACCINATION; VIRUS EXANTHEMA;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; DIAGNOSIS, DIFFERENTIAL; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; PHARMACEUTICAL PREPARATIONS; PRESCRIPTION DRUGS; PROGNOSIS; RISK FACTORS; STEVENS-JOHNSON SYNDROME;

EID: 77953546376     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2010.04.004     Document Type: Review

References (64)

1. Beylot C., Bioulac P., and Doutre M.S. [Acute generalized exanthematic pustuloses (four cases) (author's transl)]. Ann Dermatol Venereol 107 (1980) 37 [in French]
2. Baker H., and Ryan T.J. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br J Dermatol 80 (1968) 771
3. Beltraminelli H.S., Lerch M., Arnold A., et al. Acute generalized exanthematous pustulosis induced by the antifungal terbinafine: case report and review of the literature. Br J Dermatol 152 (2005) 780
4. Guevara-Gutierrez E., Uribe-Jimenez E., Diaz-Canchola M., et al. Acute generalized exanthematous pustulosis: report of 12 cases and literature review. Int J Dermatol 48 (2009) 253
5. Halevy S., Cohen A., and Livni E. Acute generalized exanthematous pustulosis associated with polysensitivity to paracetamol and bromhexine: the diagnostic role of in vitro interferon-gamma release test. Clin Exp Dermatol 25 (2000) 652
6. Paradisi A., Bugatti L., Sisto T., et al. Acute generalized exanthematous pustulosis induced by hydroxychloroquine: three cases and a review of the literature. Clin Ther 30 (2008) 930
7. Sidoroff A., Dunant A., Viboud C., et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol 157 (2007) 989
8. Sidoroff A., Halevy S., Bavinck J.N., et al. Acute generalized exanthematous pustulosis (AGEP)-a clinical reaction pattern. J Cutan Pathol 28 (2001) 113
9. Sneddon I.B., and Wilkinson D.S. Subcorneal pustular dermatosis. Br J Dermatol 68 (1956) 385
10. Britschgi M., and Pichler W.J. Acute generalized exanthematous pustulosis, a clue to neutrophil-mediated inflammatory processes orchestrated by T cells. Curr Opin Allergy Clin Immunol 2 (2002) 325
11. Britschgi M., Steiner U.C., Schmid S., et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest 107 (2001) 1433
12. Pichler W.J., and Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 59 (2004) 809
13. Chang S.L., Huang Y.H., Yang C.H., et al. Clinical manifestations and characteristics of patients with acute generalized exanthematous pustulosis in Asia. Acta Derm Venereol 88 (2008) 363
14. Davidovici B., Dodiuk-Gad R., Rozenman D., et al. Profile of acute generalized exanthematous pustulosis in Israel during 2002-2005: results of the RegiSCAR Study. Isr Med Assoc J 10 (2008) 410
15. Lerch M., and Bircher A.J. Systemically induced allergic exanthem from mercury. Contact Dermatitis 50 (2004) 349
16. Davidovici B.B., Pavel D., Cagnano E., et al. Acute generalized exanthematous pustulosis following a spider bite: report of 3 cases. J Am Acad Dermatol 55 (2006) 525
17. Auquier-Dunant A., Mockenhaupt M., Naldi L., et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 138 (2002) 1019
18. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 68 (1956) 355
19. Rzany B., Correia O., Kelly J.P., et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 353 (1999) 2190
20. La Grenade L., Lee L., Weaver J., et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf 28 (2005) 917
21. Roujeau J.C., Kelly J.P., Naldi L., et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333 (1995) 1600
22. Aguiar D., Pazo R., Duran I., et al. Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider. J Neurooncol 66 (2004) 345
23. Aydin F., Cokluk C., Senturk N., et al. Stevens-Johnson syndrome in two patients treated with cranial irradiation and phenytoin. J Eur Acad Dermatol Venereol 20 (2006) 588
24. Chung W.H., Hung S.I., Hong H.S., et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428 (2004) 486
25. Man C.B., Kwan P., Baum L., et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 48 (2007) 1015
26. Hung S.I., Chung W.H., Liou L.B., et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 102 (2005) 4134
27. Alfirevic A., Jorgensen A.L., Williamson P.R., et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 7 (2006) 813
28. Lonjou C., Borot N., Sekula P., et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 18 (2008) 99
29. Lonjou C., Thomas L., Borot N., et al. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J 6 (2006) 265
30. Lebargy F., Wolkenstein P., Gisselbrecht M., et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med 23 (1997) 1237
31. Bastuji-Garin S., Rzany B., Stern R.S., et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 129 (1993) 92
32. Magina S., Lisboa C., Leal V., et al. Dermatological and ophthalmological sequels in toxic epidermal necrolysis. Dermatology 207 (2003) 33
33. Oplatek A., Brown K., Sen S., et al. Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res 27 (2006) 26
34. Chung W.H., Hung S.I., Yang J.Y., et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 14 (2008) 1343
35. Viard I., Wehrli P., Bullani R., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282 (1998) 490
36. Murata J., Abe R., and Shimizu H. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J Allergy Clin Immunol 122 (2008) 992
37. Halevy S., Ghislain P.D., Mockenhaupt M., et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 58 (2008) 25
38. Mockenhaupt M., Viboud C., Dunant A., et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 128 (2008) 35
39. Levi N., Bastuji-Garin S., Mockenhaupt M., et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics 123 (2009) e297
40. Ball R., Ball L.K., Wise R.P., et al. Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system. Pediatr Infect Dis J 20 (2001) 219
41. Tennis P., and Stern R.S. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 49 (1997) 542
42. Garcia-Doval I., LeCleach L., Bocquet H., et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?. Arch Dermatol 136 (2000) 323
43. Palmieri T.L., Greenhalgh D.G., Saffle J.R., et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil 23 (2002) 87
44. Bachot N., Revuz J., and Roujeau J.C. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 139 (2003) 33
45. Prins C., Gelfand E.W., and French L.E. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venereol 87 (2007) 206
46. Al-Mutairi N., Arun J., Osama N.E., et al. Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis. Int J Dermatol 43 (2004) 847
47. Brown K.M., Silver G.M., Halerz M., et al. Toxic epidermal necrolysis: does immunoglobulin make a difference?. J Burn Care Rehabil 25 (2004) 81
48. Campione E., Marulli G.C., Carrozzo A.M., et al. High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm Venereol 83 (2003) 430
49. Prins C., Kerdel F.A., Padilla R.S., et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 139 (2003) 26
50. Schneck J., Fagot J.P., Sekula P., et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 58 (2008) 33
51. Shortt R., Gomez M., Mittman N., et al. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 25 (2004) 246
52. Tan A.W., Thong B.Y., Yip L.W., et al. High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series. J Dermatol 32 (2005) 1
53. Trent J.T., Kirsner R.S., Romanelli P., et al. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami Experience. Arch Dermatol 139 (2003) 39
54. Mangla K., Rastogi S., Goyal P., et al. Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study. Indian J Dermatol Venereol Leprol 71 (2005) 398
55. Tristani-Firouzi P., Petersen M.J., Saffle J.R., et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 47 (2002) 548
56. Hashim N., Bandara D., Tan E., et al. Early cyclosporine treatment of incipient toxic epidermal necrolysis induced by concomitant use of lamotrigine and sodium valproate. Acta Derm Venereol 84 (2004) 90
57. Robak E., Robak T., Gora-Tybor J., et al. Toxic epidermal necrolysis in a patient with severe aplastic anemia treated with cyclosporin A and G-CSF. J Med 32 (2001) 31
58. Sheridan R.L., Schulz J.T., Ryan C.M., et al. Long-term consequences of toxic epidermal necrolysis in children. Pediatrics 109 (2002) 74
59. Sotozono C., Ueta M., Koizumi N., et al. Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications. Ophthalmology 116 (2009) 685
60. Kardaun S.H., and Jonkman M.F. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 87 (2007) 144
61. Wolkenstein P., Chosidow O., Flechet M.L., et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 35 (1996) 234
62. Kano Y., Hirahara K., Mitsuyama Y., et al. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 62 (2007) 1439
63. Zawodniak A., Lochmatter P., Yerly D., et al. In vitro detection of cytotoxic T and NK cells in peripheral blood of patients with various drug-induced skin diseases. Allergy 65 (2010) 376-384
64. Bastuji-Garin S., Fouchard N., Bertocchi M., et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 115 (2000) 149